Drug-induced Fatty Liver Disease: Pathogenesis and Treatment.

Authors :: Kolaric TO
Nincevic V
Kuna L
Duspara K
Bojanic K
Vukadin S
Raguz-Lucic N
Wu GY
Smolic M
Source :: Journal of clinical and translational hepatology [J Clin Transl Hepatol] 2021 Oct 28; Vol. 9 (5), pp. 731-737. Date of Electronic Publication: 2021 Sep 14.
Publication Year :: 2021
Abstract: Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing incidence of polypharmacy, especially in the elderly, has greatly increased the risk of drug-induced liver injury (DILI) in general, and drug-induced fatty liver disease (DIFLD) in particular. This review focuses on the contribution of DIFLD to DILI in terms of epidemiology, pathophysiology, the most common drugs associated with DIFLD, and treatment strategies.<br />Competing Interests: The authors have no conflict of interests related to this publication.<br /> (© 2021 Authors.)